New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

DMD
Regenxbio reports new data from ongoing Phase I/II gene therapy trial in DMD • Source: Shutterstock

More from Gene Therapies

More from Therapy Areas